Slide 1 Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple negative…

Slide 1 Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting Abstracts Presented By Sonali Smith at 2014 ASCO Annual Meeting Diffuse Large…

Slide 1 Presented By Christina Tsien at 2014 ASCO Annual Meeting Current Limitations in the Response Assessment of Anti-Angiogenic Therapy Presented By Christina Tsien at…

Slide 1 E1308:A Phase II Trial of Induction Chemotherapy Followed by Cetuximab with Low Dose vs. Standard Dose IMRT in Patients with HPV-Associated Resectable Squamous Cell…

Slide 1 Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi at 2014…

Slide 1 Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris Winterhoff…

Slide 1 Highlights of the Day:Central Nervous System Tumors Presented By Michael Prados at 2014 ASCO Annual Meeting Slide 2 Presented By Michael Prados at 2014 ASCO Annual…

Slide 1 Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting Metastatic Cervical Cancer Presented By Christian Hinrichs at 2014 ASCO Annual Meeting Adoptive…

Slide 1 Managing Comorbidities In Oncology: A multisite randomized controlled trial of continuing vs.discontinuing statins in the setting of life-limiting illness Presented…

Slide 1 First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their…